U.S. flag

An official website of the United States government

NC_000019.9:g.(?_54626515)_(54627192_?)del AND not provided

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Jul 7, 2022
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV003119639.5

Allele description [Variation Report for NC_000019.9:g.(?_54626515)_(54627192_?)del]

NC_000019.9:g.(?_54626515)_(54627192_?)del

Gene:
PRPF31:pre-mRNA processing factor 31 [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
19q13.42
Genomic location:
Chr19: 54626515 - 54627192 (on Assembly GRCh37)
Preferred name:
NC_000019.9:g.(?_54626515)_(54627192_?)del
HGVS:
NC_000019.9:g.(?_54626515)_(54627192_?)del

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

  • Bunyaviridae Infections
    Bunyaviridae Infections
    Virus diseases caused by the BUNYAVIRIDAE.<br/>Year introduced: 1992
    MeSH

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV003794090Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Pathogenic
(Jul 7, 2022)
germlineclinical testing

PubMed (6)
[See all records that cite these PMIDs]

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Identification of a novel pathogenic missense mutation in PRPF31 using whole exome sequencing: a case report.

Bryant L, Lozynska O, Marsh A, Papp TE, van Gorder L, Serrano LW, Gai X, Maguire AM, Aleman TS, Bennett J.

Br J Ophthalmol. 2019 Jun;103(6):761-767. doi: 10.1136/bjophthalmol-2017-311405. Epub 2018 Jul 20.

PubMed [citation]
PMID:
30030392
PMCID:
PMC6582727

Mutation Analysis of Pre-mRNA Splicing Genes PRPF31, PRPF8, and SNRNP200 in Chinese Families with Autosomal Dominant Retinitis Pigmentosa.

Wu Z, Zhong M, Li M, Huang H, Liao J, Lu A, Guo K, Ma N, Lin J, Duan J, Liu L, Xu F, Zhong Z, Chen J.

Curr Mol Med. 2018;18(5):287-294. doi: 10.2174/1566524018666181024160452.

PubMed [citation]
PMID:
30360737
See all PubMed Citations (6)

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV003794090.3

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (6)

Description

For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the PRPF31 protein in which other variant(s) (p.Leu197Pro) have been determined to be pathogenic (PMID: 30030392, 30360737). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with PRPF31-related conditions. This variant results in the deletion of exon 6 and part of exon 7 (c.421-318_592del) of the PRPF31 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PRPF31 are known to be pathogenic (PMID: 18317597, 23950152).

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024